Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States
Open Access
- 23 September 2026
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10) , e70732
Abstract
Sickle cell disease (SCD) is a debilitating hereditary hematologic disorder characterized by severe physical complications, including painful vaso‐occlusive crises, chronic pain, multi‐organ damage, and reduced life expectancy. Diverse medications are prescribed to treat SCD or manage its associated complications. However, no comprehensive resource for concomitant medication and drug–drug interaction (DDI) risk exists for people living with SCD. Here, we utilized real‐world claims data from the Merative Commercial MarketScan Research Database to identify the 100 most prescribed drugs for adolescents and adults living with SCD in the United States with commercial health insurance. DDI risks were assessed by leveraging the CERTARA Drug Interaction Database. In total, 43/100 drugs on the list were associated with DDI risks. Inhibitors were more frequently represented than inducers, suggesting that interaction risk in this population may be driven primarily by inhibition‐mediated mechanisms. CYP3A4 accounted for the largest proportion of identified interactions. The high prescription rates of the CYP3A4 substrates oxycodone (40%) and fentanyl (18.5%), associated with potentially serious clinical consequences due to DDIs, highlight the importance of considering CYP3A4 interaction risk during development of novel therapies for SCD. Overall, this analysis provides a population‐level insight into prescription patterns and subsequent DDI risks for people living with SCD. We expect these findings to (1) create clinical DDI risk awareness for this population and (2) inform strategic planning of DDI assessments during development of novel therapies indicated for SCD.Keywords
This publication has 22 references indexed in Scilit:
- Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient PopulationsClinical Pharmacology & Therapeutics, 2025
- Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry PerspectiveClinical Pharmacology & Therapeutics, 2023
- Trends in Clinical Pharmacology and TherapeuticsClinical Pharmacology & Therapeutics, 2023
- Severe CNS depression with duloxetine, ciprofloxacin and CYP2D6 deficiency—role and recognition of drug-drug-gene interactionsEuropean Journal of Clinical Pharmacology, 2022
- Drugs in COVID‐19 Clinical Trials: Predicting Transporter‐Mediated Drug‐Drug Interactions Using In Vitro Assays and Real‐World DataClinical Pharmacology & Therapeutics, 2021
- Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance databaseEuropean Journal of Clinical Pharmacology, 2021
- Respiratory depression related to multiple drug–drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodoneEuropean Journal of Clinical Pharmacology, 2017
- Evolution of sickle cell disease from a life‐threatening disease of children to a chronic disease of adults: The last 40 yearsAmerican Journal of Hematology, 2015
- Proportion of Adults With Sickle Cell Anemia and Pain Crises Receiving HydroxyureaJAMA, 2015
- Possible fluconazole–fentanyl interaction—a case reportEuropean Journal of Clinical Pharmacology, 2006